Intas Pharma's Dehradun facility receives USFDA warning letter. USFDA cites lapses in quality systems and data integrity. New US approvals halted until compliance issues are resolved. Did our AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results